Trial Profile
The Efficacy and Safety of Lenalidomide (Revlimid) Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome Associated With Del (5q) Cytogenetic Abnormality
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Pharmacogenomic; Therapeutic Use
- 13 Jun 2019 Trial has been completed in UK.
- 26 Feb 2019 Status changed from active, no longer recruiting to completed.
- 01 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.